Neuronetics (NASDAQ:STIM – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Neuronetics to related businesses based on the strength of its dividends, institutional ownership, earnings, risk, analyst recommendations, profitability and valuation.
Analyst Ratings
This is a summary of current recommendations and price targets for Neuronetics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuronetics | 1 | 0 | 4 | 0 | 2.60 |
| Neuronetics Competitors | 4242 | 10442 | 18140 | 818 | 2.46 |
Neuronetics currently has a consensus price target of $4.67, suggesting a potential upside of 106.49%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 24.45%. Given Neuronetics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Neuronetics is more favorable than its peers.
Institutional & Insider Ownership
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Neuronetics and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Neuronetics | $149.16 million | -$39.00 million | -5.14 |
| Neuronetics Competitors | $1.89 billion | $138.15 million | 11.18 |
Neuronetics’ peers have higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Neuronetics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Neuronetics’ peers have a beta of 2.52, meaning that their average share price is 152% more volatile than the S&P 500.
Profitability
This table compares Neuronetics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuronetics | -19.62% | -125.11% | -22.15% |
| Neuronetics Competitors | -278.47% | -150.38% | -22.01% |
Summary
Neuronetics peers beat Neuronetics on 7 of the 13 factors compared.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
